feinstein, northwell
Northwell Health's Feinstein Institutes for Medical Research is beginning three studies alongside Sanofi, Gilead Sciences and Regeneron Pharmaceuticals. These studies will test possible treatments for moderate and severe cases of COVID-19. (Photo via Northwell Health)

Northwell Health’s Feinstein Institutes Teams Up with Sanofi, Regeneron Pharmaceuticals, Gilead Sciences to Test COVID-19 Treatments

The research arm of Northwell Health (No. 2 on DiversityInc’s 2019 Top Hospitals & Health Systems), the Feinstein Institutes for Medical Research, is partnering with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi (No. 31 on DiversityInc’s 2019 Top 50 Companies for Diversity) to identify treatments for people hospitalized with moderate to severe cases of the novel coronavirus (COVID-19).

The Feinstein Institutes announced last week the enrollment of three clinical trials aimed at finding an effective treatment for those diagnosed with the coronavirus. Due to the urgency of the issue, there has been a nationwide push for expedited Food and Drug Administration (FDA) approvals of experimental COVID-19 therapies. However, Northwell Health and the Feinstein Institutes announced the trials would continue through the typical, lengthier process to ensure accuracy.

Two of the trials, which will be conducted with Gilead, will involve the drug remdesivir. Remdesivir is an antiviral drug that is designed to reduce the length and intensity of a COVID-19 infection. Northwell Health said the drug had shown promise in working against similar viruses like MERS and SARS in test tubes and animal models. The first trial has room for 400 subjects with severe cases of COVID-19 worldwide. Researchers will administer the drug intravenously in two different durations and measure patients’ bodies’ responses. Feinstein Institutes’ Marcia Epstein, MD, an infectious disease expert, will lead this study.

The other Gilead remdesivir trial will assess two different durations of treatment with the drug and compare it to the current treatment methods in up to 600 patients with moderate cases of COVID-19. Researchers will also look at improvement of symptoms and time of discharge. Prashant Malhotra, MD, will lead this study. Malhotra is an assistant professor of the Institute of Health Innovations & Outcomes Research at Feinstein Institutes and is an infectious disease expert.

In the third study, Feinstein will collaborate with Regeneron and Sanofi. The trial will look at approximately 400 severe or critical cases of COVID-19 in hospitals across the U.S. This trial will study the efficacy of a human antibody called sarilumab that may help prevent complications connected to severe pneumonia in COVID-19 patients. This study adds to a preliminary Chinese trial that found the use of the antibody helped reduce fever in all patients.

China has approved its use to treat patients with severe or critical cases. Negin Hajizadeh, MD, an assistant professor in the Institute of Health Innovations & Outcomes Research and a pulmonary critical care doctor will be leading this study.

To read more about these studies and Northwell’s plans to combat COVID-19, visit northwell.edu.

Latest News

woke politics

Republicans Launch a War on ‘Woke’ Politics in Hopes of Big Legislative Wins in 2022

In 2020, former President Barack Obama warned that the phrase “Defund the Police” could become a dangerous rallying cry for the conservative right. But now, Republicans have apparently taken that warning one step further, declaring war on all things “woke.” Allan Smith and Sahil Kapur of NBC News wrote that…

women in politics

Women Remain Vastly Underrepresented in Local Government, Despite Conventional Wisdom Suggesting Otherwise

Vice President Kamala Harris and Speaker of the House Nancy Pelosi sat behind President Biden during his first speech to a joint session of Congress on April 28 — representing the first time two women held such important and high-ranking political offices. Even after such a historic moment, the reality…

voter restriction

Florida Follows Georgia’s Lead, Approves Racist Anti-Voter Restrictions Aimed Primarily at Democrats and People of Color

Not content with letting Georgia be the only state in the South demonized for its bigoted and racist attacks on voter rights, Florida has jumped into the fray in issuing its own series of new and highly controversial “Jim Crow-esque” anti-voting restrictions aimed specifically at disenfranchising Democrats and voters of…

Kentucky Derby

Inspired by Protests Over Breonna Taylor’s Death, Humana and Kentucky Derby Festival Launch Diversity and Inclusion Initiative in Louisville

Ahead of the 147th Kentucky Derby on Saturday, May 1, Kentucky Derby officials and Humana (No. 25 on The DiversityInc Top 50 Companies for Diversity list in 2020) have announced a new equity initiative meant to make the race more accessible and welcoming to everyone, regardless of race, gender, age…

crimes against human ity

‘Crime Against Humanity’; Global Report Says the US Should Be Prosecuted in International Criminal Court for Ongoing Police Murders of Black Americans

In what has been described as a “devastating” report, human rights experts and lawyers have investigated and released a 188-page analysis of the ongoing police brutality and killing of Black Americans in the U.S. Their verdict: the country is guilty of “crimes against humanity” and should be prosecuted for its…

Tokyo, Olympics

Tokyo Olympics to Encourage Significant Increase in Gender Equality Among Event’s Corporate Sponsors

Besides simply being a showcase for some of the most talented and athletic men and women on the planet, the organizers of the Tokyo Olympics are hoping their event this summer can also help promote significant change in corporate culture, both in Japan and around the globe. Bloomberg’s Ayai Tomisawa…